# Orin M. Goldblum

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/orin-m-goldblum/

## Facts

| Field | Value |
| --- | --- |
| Citations | 1,671 |
| Field | Psoriasis: Treatment and Pathogenesis |
| h-index | 23 |
| i10-index | 37 |
| Last Known Institution | Eli Lilly (United States) |
| OpenAlex ID | https://openalex.org/A5002658384 |
| ORCID iD | 0000-0003-1827-2031 |
| Works | 71 |

## Researcher papers

- [Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis](https://scholariq.org/papers/efficacy-and-safety-of-adalimumab-across-subgroups-of-patients-with-moderate-to/)
- [Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)](https://scholariq.org/papers/baricitinib-in-patients-with-moderate-to-severe-atopic-dermatitis-results-from-a/)
- [Factors affecting sleep quality in patients with psoriasis](https://scholariq.org/papers/factors-affecting-sleep-quality-in-patients-with-psoriasis/)
- [Ixekizumab treatment improves fingernail psoriasis in patients with moderate‐to‐severe psoriasis: results from the randomized, controlled and open‐label phases of <scp>UNCOVER</scp>‐3](https://scholariq.org/papers/ixekizumab-treatment-improves-fingernail-psoriasis-in-patients-with-moderate-to/)
- [Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis](https://scholariq.org/papers/improvement-of-scalp-and-nail-lesions-with-ixekizumab-in-a-phase-2-trial-in/)
- [Sleep quality and other patient‐reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open‐label Phase IIIB trial](https://scholariq.org/papers/sleep-quality-and-other-patient-reported-outcomes-improve-after-patients-with/)
- [Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study](https://scholariq.org/papers/maintenance-of-skin-clearance-with-ixekizumab-treatment-of-psoriasis-three-year/)
- [Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3](https://scholariq.org/papers/ixekizumab-treatment-shows-a-neutral-impact-on-cardiovascular-parameters-in/)
- [Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3)](https://scholariq.org/papers/sustained-response-with-ixekizumab-treatment-of-moderate-to-severe-psoriasis/)
- [Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti‐tumour necrosis factor agents: subanalysis of BELIEVE](https://scholariq.org/papers/efficacy-and-safety-of-adalimumab-in-patients-with-psoriasis-previously-treated/)
- [US health care utilization and costs in adult patients with atopic dermatitis by disease severity](https://scholariq.org/papers/us-health-care-utilization-and-costs-in-adult-patients-with-atopic-dermatitis-by/)

## Researcher topics

- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)
- [Allergic Rhinitis and Sensitization](https://scholariq.org/topics/allergic-rhinitis-and-sensitization/)
- [Autoimmune Bullous Skin Diseases](https://scholariq.org/topics/autoimmune-bullous-skin-diseases/)

## Researcher university

- [Eli Lilly (United States)](https://scholariq.org/institutions/eli-lilly-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.